France

MaaT Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

USP Workshop 2021

Participation Not Confirmed

Update your events

MaaT Pharma Announces Series B Extension and Final Closing with Total of €25 Million ($29.5 Million)

Lead Product(s): MaaT013

Therapeutic Area: Immunology Product Name: MaaT013

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Bpifrance

Deal Size: $29.5 million Upfront Cash: Undisclosed

Deal Type: Series B Financing December 01, 2020

Details:

The final closing of the Series B financing will support the advancement of an innovative fermentation production platform to develop and manufacture both “standard” high-richness, high-diversity fermented product MaaT013, and a pipeline of indication-specific candidates.

MaaT Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

USP Workshop 2021

Participation Not Confirmed

Update your events

MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at EBMT 2020

Lead Product(s): MaaT013

Therapeutic Area: Immunology Product Name: MaaT013

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 28, 2020

Details:

Data from the Company’s compassionate use program with MaaT013 as a treatment in patients with intestinal acute Graft-versus-Host-Disease will be highlighted in an e-poster presentation.

OSE Immunotherapeutics SA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

USP Workshop 2021

Participation Not Confirmed

Update your events

OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement

Lead Product(s): OSE-127

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Servier

Deal Size: $21.4 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 17, 2020

Details:

In December 2016, OSE Immunotherapeutics granted Servier a two-step option agreement to acquire the exclusive worldwide license to develop and commercialize OSE-127.